Results 261 to 270 of about 6,349,043 (393)

An Experience on the Biological Assay of the Toxicity of Imported Fugu (Tetrodon)

, 1973
Hironoshin Kawasaki, Tadashi Nagata, Seizaburo KANOH   +2 more
openalex   +2 more sources

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Studies on the biological assay of the Human Chorionic Gonadotropin in immature female mice.

, 1972
Morio Kubomichi
openalex   +2 more sources

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Rapid and Highly Sensitive Detection of Ricin in Biological Fluids Using Optical Modulation Biosensing. [PDF]

Biosensors (Basel)
Levy E, Golani-Zaidie L, Burg S, Makdasi E, Alcalay R, Falach R, Schuster O, Danielli A.   +7 more
europepmc   +1 more source

A method of conducting a biological assay on a preparation giving repeated graded responses illustrated by the estimation of histamine

Journal of Physiology, 1942
H. Schild
semanticscholar   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Evaluation of the Effectiveness of Chitosan-Modified Bone Regeneration Materials: A Systematic Review. [PDF]

Pharmaceutics
Gerova-Vatsova T, Peev S, Yotsova R, Rogova VV.   +3 more
europepmc   +1 more source

Biologic allergen assay for in vivo test allergens with an in vitro model of the murine type I reaction☆☆☆★ [PDF]

, 1997
Andreas Hoffmann, S. Vieths, Dieter Haustein   +2 more
openalex   +1 more source